Phospho-CREB1 (Ser129) Antibody

What is Phospho-CREB1 (Ser129) Antibody and what does it detect?

Phospho-CREB1 (Ser129) antibody is a specialized immunological reagent designed to detect endogenous levels of CREB1 protein only when phosphorylated at serine residue 129 (S129) . This site-specific antibody recognizes the phosphorylated form of CREB1, a 43 kDa basic/leucine zipper transcription factor that binds to the cyclic AMP response element (CRE) and activates transcription in response to various extracellular signals . The antibody does not recognize the non-phosphorylated form of CREB1 at this particular site, making it highly specific for studying this post-translational modification . CREB1 is involved in numerous cellular processes including circadian rhythm regulation, adipocyte differentiation, and functions related to learning and memory . These antibodies are typically generated using synthetic phosphopeptides derived from the region surrounding the Ser129 site (commonly amino acids 96-145) of human CREB1 .

How does phosphorylation at Ser129 compare with other CREB1 phosphorylation sites?

Phosphorylation of CREB1 occurs at multiple serine residues, with each site potentially regulating different aspects of CREB1 function. While Ser133 phosphorylation is the most extensively studied and is critical for activation of CREB-dependent transcription, phosphorylation at Ser129 has been shown to positively affect CREB transcriptional activity in a manner distinct from Ser133 . Interestingly, phosphorylation at different sites within the kinase-inducible domain (KID) of CREB1 can have opposing effects on transcriptional activity; phosphorylation at Ser129 and Ser133 enhances transcriptional activity, whereas phosphorylation at Ser111 and Ser121 inhibits CREB-related gene expression . This complex pattern of regulatory phosphorylation highlights the importance of studying site-specific modifications like Ser129 to fully understand CREB-mediated transcriptional regulation in different cellular contexts.

What are the common applications for Phospho-CREB1 (Ser129) Antibody?

Phospho-CREB1 (Ser129) antibodies are versatile research tools applicable across multiple experimental approaches. The most common applications include Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA) . For Western blot applications, these antibodies are typically used at dilutions ranging from 1:500 to 1:2000, allowing researchers to detect the phosphorylated form of CREB1 in cell or tissue lysates . In immunohistochemistry, the recommended dilutions are generally between 1:50 and 1:300, enabling visualization of phosphorylated CREB1 in fixed tissue sections . For immunofluorescence, dilutions between 1:100 and 1:1000 are commonly used to examine subcellular localization of phosphorylated CREB1 . These antibodies have been successfully used to study CREB1 phosphorylation in various research contexts, including cancer research, neuroscience, and studies of metabolic disorders.

What controls should be used when validating the specificity of Phospho-CREB1 (Ser129) Antibody?

When validating the specificity of Phospho-CREB1 (Ser129) antibody, multiple controls should be implemented to ensure reliable results. A critical positive control involves treating cells with stimuli known to induce Ser129 phosphorylation, such as UV radiation, which can be detected as shown in Western blot analyses of 293 cells . Conversely, untreated cells serve as negative controls to establish baseline phosphorylation levels . Peptide competition assays provide another essential validation method, where pre-incubation of the antibody with the phosphorylated peptide used as the immunogen should abolish specific staining, as demonstrated in immunohistochemical analyses of human breast carcinoma tissue . Additionally, when evaluating tissue samples, including adjacent normal tissue sections can help distinguish specific staining patterns from background noise, particularly important in complex tissues like breast carcinoma .

For advanced validation, phosphatase treatment of protein samples should eliminate antibody recognition if the antibody is truly phospho-specific. Similarly, CREB1 knockdown experiments using siRNA can confirm signal specificity by demonstrating reduced antibody binding. These multi-layered validation approaches ensure that experimental findings reflect genuine Ser129 phosphorylation rather than non-specific antibody interactions or technical artifacts.

How do monoclonal and polyclonal Phospho-CREB1 (Ser129) antibodies differ in experimental outcomes?

In immunohistochemistry applications, monoclonal antibodies typically generate cleaner background with more consistent staining patterns across experiments, while polyclonal antibodies might provide higher sensitivity but occasionally with increased background . For challenging applications like detecting low-abundance phosphorylated CREB1 in brain tissue samples, researchers might prefer the higher sensitivity of polyclonal antibodies, whereas studies requiring absolute specificity between phosphorylation at Ser129 versus Ser133 might benefit from monoclonal antibodies. The choice between these antibody types should be guided by the specific experimental requirements, available validation data, and the particular research question being addressed.

What factors affect the detection sensitivity when using Phospho-CREB1 (Ser129) Antibody?

Multiple factors can significantly influence detection sensitivity when using Phospho-CREB1 (Ser129) antibody in research applications. Sample preparation protocols play a crucial role, particularly the inclusion of phosphatase inhibitors during cell or tissue lysis to preserve the phosphorylation status of CREB1 . The timing of sample collection is equally important, as phosphorylation events are often transient; this necessitates careful experimental design to capture the relevant phosphorylation window. Fixation methods in immunohistochemistry and immunofluorescence applications can dramatically affect epitope accessibility, with overfixation potentially masking the phospho-epitope . Different antibody clones demonstrate varying affinities for the phosphorylated epitope, with purification methods impacting final antibody quality—affinity-purified antibodies generally offer superior sensitivity compared to crude antisera .

Technical parameters such as antibody concentration, incubation time, temperature, and blocking reagents require optimization for each experimental system. The detection system employed (chemiluminescence, fluorescence, or colorimetric) also influences sensitivity thresholds. Additionally, the abundance of phosphorylated CREB1 at Ser129 varies across cell types and stimulation conditions, necessitating protocol adjustments when transitioning between experimental models. Systematic optimization of these parameters is essential for maximizing detection sensitivity while maintaining specificity for phosphorylated Ser129.

How can Phospho-CREB1 (Ser129) Antibody be used to investigate CREB dysregulation in neurodegenerative diseases?

Phospho-CREB1 (Ser129) antibodies offer valuable insights into CREB dysregulation in neurodegenerative conditions through multiple methodological approaches. In Alzheimer's Disease, where CREB dysfunction has been implicated in pathophysiology, these antibodies can be employed in comparative immunohistochemistry studies to quantify altered phosphorylation patterns across brain regions . Researchers should implement double-labeling immunofluorescence techniques to investigate co-localization of phosphorylated CREB1 with disease-specific markers, such as phospho-alpha-synuclein (S129) in Parkinson's Disease, as demonstrated in studies examining molecular signatures of altered energy metabolism and circadian rhythm disruption . This approach allows for spatial correlation between CREB phosphorylation status and pathological features.

Advanced tissue analysis can be conducted using both manual and automated quantification methods. For instance, QuPath software enables precise quantification of CREBBP-positive cells as a percentage of total cells in defined regions of interest (ROIs), with care taken to exclude blood vessels and neuromelanin from the analysis . When examining the relationship between CREB phosphorylation and disease progression, it is crucial to perform these analyses blinded to case diagnosis to prevent observer bias. The correlation between phosphorylated CREB1 levels and clinical parameters can provide mechanistic insights into how CREB dysregulation contributes to disease pathogenesis, potentially revealing novel therapeutic targets or biomarkers for neurodegenerative conditions.

What are the methods to detect simultaneous phosphorylation at multiple sites in CREB1?

Mass spectrometry-based phosphoproteomics offers the most comprehensive approach for analyzing multi-site phosphorylation patterns. This technique can quantitatively assess the stoichiometry of different phosphorylation combinations across the CREB1 protein. Sample preparation typically involves immunoprecipitation with a total CREB1 antibody followed by tryptic digestion and phosphopeptide enrichment using titanium dioxide (TiO2) or immobilized metal affinity chromatography (IMAC). For functional studies, researchers can employ site-directed mutagenesis to create phosphomimetic (serine to glutamic acid) or phospho-deficient (serine to alanine) CREB1 variants at multiple sites, allowing examination of how different phosphorylation combinations affect transcriptional activity. These complementary approaches provide a comprehensive understanding of how complex phosphorylation patterns, including at Ser129, collectively regulate CREB1 function.

How does the interplay between CREB1 phosphorylation and other post-translational modifications affect experimental interpretation?

The interplay between CREB1 phosphorylation at Ser129 and other post-translational modifications (PTMs) creates a complex regulatory network that significantly impacts experimental interpretation. CREB1 function is modulated through various PTMs including multiple phosphorylation events, acetylation, SUMOylation, and glycosylation, each potentially influencing the others. Research has revealed important interactions, such as the relationship between CREB1 and SIRT1, where SIRT1 deacetylates CREB1 and subsequently suppresses its phosphorylation, thereby downregulating CREB-related gene expression . This highlights how acetylation status can directly affect phosphorylation detection using Phospho-CREB1 (Ser129) antibodies.

To address these complex interactions experimentally, researchers should implement comprehensive PTM profiling approaches. This includes conducting parallel immunoprecipitation experiments with antibodies targeting different modifications followed by reciprocal Western blotting. For instance, immunoprecipitating with acetyl-CREB antibodies followed by probing with Phospho-CREB1 (Ser129) antibody can reveal whether these modifications coexist on the same CREB1 molecules. Additionally, treating samples with specific inhibitors of modifying enzymes (histone deacetylase inhibitors, kinase inhibitors, phosphatase inhibitors) before analysis can help dissect the hierarchical relationships between modifications. Mass spectrometry analysis remains the gold standard for comprehensive PTM mapping, capable of identifying combinatorial modification patterns on individual CREB1 molecules. Understanding these interrelationships is crucial for correctly interpreting experimental data and elucidating the functional consequences of Ser129 phosphorylation in different cellular contexts.

What is the recommended sample preparation protocol for optimal detection of phosphorylated CREB1 at Ser129?

Optimal detection of phosphorylated CREB1 at Ser129 requires meticulous sample preparation to preserve this potentially labile modification. For cell culture samples, rapid harvesting is essential, ideally using direct lysis in hot SDS buffer (95°C) containing comprehensive phosphatase inhibitor cocktails that target both serine/threonine and tyrosine phosphatases . This approach instantaneously inactivates cellular phosphatases that might otherwise dephosphorylate CREB1 during processing. For tissue samples, flash-freezing in liquid nitrogen immediately after collection followed by homogenization in RIPA buffer supplemented with sodium fluoride (50 mM), sodium orthovanadate (1 mM), and β-glycerophosphate (10 mM) helps maintain phosphorylation status. When working with brain tissue, where CREB1 plays crucial neurological roles, the addition of okadaic acid (1 μM) can provide further protection against specific phosphatases abundant in neural tissues .

Protein quantification should be performed using methods compatible with phosphatase inhibitors, such as BCA assay rather than Bradford, which can be affected by these additives. For Western blotting applications, equal protein loading (typically 20-50 μg) and transfer to PVDF membranes (preferred over nitrocellulose for phospho-epitopes) optimizes detection. When preparing samples for immunohistochemistry or immunofluorescence, phosphorylation-preserving fixatives should be employed, with brief paraformaldehyde fixation (4%, 10-15 minutes) generally yielding better results than prolonged formalin fixation, which can mask phospho-epitopes through excessive cross-linking . These carefully optimized preparation protocols significantly improve the reliability and sensitivity of phosphorylated CREB1 detection across experimental platforms.

How can researchers troubleshoot common issues with Phospho-CREB1 (Ser129) Antibody applications?

Troubleshooting Phospho-CREB1 (Ser129) antibody applications requires systematic evaluation of multiple experimental parameters. When facing weak or absent signals in Western blotting, researchers should first verify phosphorylation stimulus effectiveness, as demonstrated in studies comparing untreated cells with UV-treated samples that show enhanced phosphorylation . Increasing protein loading (up to 80-100 μg), extending primary antibody incubation (overnight at 4°C), or implementing signal enhancement systems like biotin-streptavidin amplification can improve detection sensitivity. For high background issues, optimizing blocking conditions (typically 5% BSA rather than milk, which contains phosphoproteins) and increasing wash duration/stringency often proves effective. If multiple bands appear, confirming the expected molecular weight (approximately 43 kDa for CREB1) and potentially performing siRNA knockdown validation helps distinguish specific from non-specific signals .

In immunohistochemistry applications, antigen retrieval methods significantly impact phospho-epitope accessibility, with citrate buffer (pH 6.0) generally working well for Phospho-CREB1 (Ser129) detection . For fixation-related issues, reducing fixation time or switching to alternative fixatives like zinc-based formulations may preserve epitope recognition. When phospho-specific staining proves difficult to distinguish from total protein, implementing peptide competition controls by pre-incubating the antibody with phosphorylated and non-phosphorylated peptides helps confirm specificity . For all applications, inclusion of positive control samples (such as UV-treated cells or tissues known to express phosphorylated CREB1) provides essential reference points for troubleshooting. These methodical approaches systematically address the common technical challenges associated with phospho-specific antibody applications.

What are the latest methodological advances in detecting CREB1 phosphorylation in complex tissue samples?

Recent methodological advances have significantly enhanced the detection of CREB1 phosphorylation in complex tissue samples. Spatial transcriptomics (ST) represents a breakthrough technology that enables simultaneous visualization of phosphorylated CREB1 and associated transcriptional changes with precise spatial resolution, particularly valuable for heterogeneous tissues like brain sections in neurodegenerative disease research . This approach allows correlation between phosphorylation patterns and regional gene expression profiles. Multiplex immunofluorescence techniques using tyramide signal amplification (TSA) or quantum dots have extended detection capabilities, allowing simultaneous visualization of multiple phosphorylation sites (e.g., Ser129 and Ser133) alongside other proteins in the same tissue section, providing insights into the colocalization of different phosphorylated forms with disease markers.

Advanced image analysis methods have transformed quantitative assessment of phosphorylated CREB1 in tissues. Machine learning algorithms implemented in platforms like QuPath enable automated identification of cell types based on morphological features, followed by quantification of nuclear phospho-CREB1 intensity with exceptional precision . These approaches can distinguish subtle differences in phosphorylation levels across different cell populations within the same tissue section. Mass spectrometry imaging (MSI) represents another frontier technology, allowing label-free detection of phosphorylated peptides directly in tissue sections with spatial resolution approaching the cellular level. For researchers studying neurodegenerative diseases, these methodological advances provide unprecedented opportunities to examine how CREB1 phosphorylation patterns correlate with pathological features like Lewy bodies per mm² of tissue, potentially revealing new insights into disease mechanisms and progression .

What is the role of CREB1 Ser129 phosphorylation in cancer biology?

CREB1 Ser129 phosphorylation plays a multifaceted role in cancer biology, with emerging evidence suggesting context-dependent functions across different malignancies. In gastric cancer (GC), CREB knockdown experiments have demonstrated significant inhibition of cell viability and colony formation in BGC-823 and SGC-790 cell lines, accompanied by G0/G1 phase arrest and suppression of downstream CREB targets including cyclin D1, BCL2, and MMP-9 . This suggests that phosphorylation-dependent CREB1 activation contributes to the proliferative and anti-apoptotic phenotypes characteristic of GC. The regulatory relationship between CREB1 and SIRT1 provides additional mechanistic insight, as SIRT1 deacetylates CREB1 and subsequently suppresses its phosphorylation, leading to downregulation of CREB-related gene expression . This interaction has been specifically linked to carbonic anhydrase 9 (CA9) expression patterns in GC.

Interestingly, immunohistochemical analyses using Phospho-CREB1 (Ser129) antibodies have shown varying staining patterns across cancer types, with particularly strong nuclear localization observed in breast carcinoma tissues . This differential expression pattern suggests tissue-specific roles for Ser129 phosphorylation. While Ser133 phosphorylation has been extensively characterized in cancer contexts, the specific contribution of Ser129 phosphorylation remains less well-defined but appears to positively affect CREB transcriptional activity . The identification of CREB as a potential therapeutic target in cancer has prompted investigation of CREB inhibitors, though the complexity of CREB regulation—including its multiple phosphorylation sites—presents challenges for targeted intervention strategies.

How does CREB1 Ser129 phosphorylation contribute to neurological function and dysfunction?

CREB1 Ser129 phosphorylation contributes significantly to both normal neurological function and pathological states. In normal physiology, CREB1 plays crucial roles in learning and memory processes through its regulation of gene expression in response to neuronal activity . While phosphorylation at Ser133 has been extensively characterized in these contexts, Ser129 phosphorylation represents an additional regulatory mechanism that positively affects CREB transcriptional activity . This phosphorylation event may provide fine-tuning of CREB-dependent gene expression in response to specific neuronal stimuli, contributing to synaptic plasticity and memory formation. The complex interplay between different phosphorylation sites, including Ser129, creates a sophisticated regulatory network that enables precise control of CREB-mediated transcription in neurons.

In pathological contexts, altered CREB1 phosphorylation has been implicated in neurodegenerative diseases, including Alzheimer's Disease . Recent spatial transcriptomics data have revealed perturbed regulation of circadian rhythm in neurodegenerative conditions, corroborated by increased immunodetection of CREB-binding proteins . The relationship between CREB1 phosphorylation and alpha-synuclein pathology has been investigated through comparative immunohistochemical analyses of CREBBP staining and phospho-alpha-synuclein (S129) in brain tissue sections . These analyses, performed with careful methodological considerations such as exclusion of blood vessels and neuromelanin from regions of interest, provide insights into how disrupted CREB signaling may contribute to disease progression. The quantification of CREBBP-positive cells as a percentage of total cells in specific brain regions, alongside assessments of Lewy body density per mm² of tissue, enables correlation between CREB dysfunction and hallmark pathological features of neurodegenerative diseases .

What emerging technologies might enhance Phospho-CREB1 (Ser129) detection and functional analysis?

Emerging technologies promise to revolutionize both the detection and functional analysis of Phospho-CREB1 (Ser129). Proximity ligation assay (PLA) represents a powerful approach for detecting protein-protein interactions contingent on specific phosphorylation states, allowing researchers to visualize associations between phosphorylated CREB1 and its binding partners like CBP or TORC coactivators with single-molecule sensitivity in situ. CRISPR-based techniques, including base editing to introduce phosphomimetic mutations at Ser129, offer unprecedented opportunities to examine the functional consequences of this modification without overexpression artifacts. Additionally, synthetic biology approaches using engineered phosphorylation-responsive transcription factors could enable real-time monitoring of Ser129 phosphorylation dynamics in living cells.

Advanced mass spectrometry techniques, particularly targeted parallel reaction monitoring (PRM), are enhancing quantitative assessment of site-specific phosphorylation with exceptional sensitivity and specificity. These approaches allow absolute quantification of Ser129 phosphorylation stoichiometry across different experimental conditions. Looking forward, integrating phospho-proteomic data with transcriptomic and epigenomic datasets through multi-omics approaches will provide comprehensive understanding of how Ser129 phosphorylation influences the broader CREB1 regulatory network. The application of artificial intelligence for image analysis in immunohistochemistry studies will likely improve detection sensitivity and reveal subtle patterns in phosphorylation distribution across different tissue regions and cell types, particularly valuable for complex samples like brain tissue in neurodegenerative disease research . These technological advances collectively promise deeper insights into the specific roles of Ser129 phosphorylation in both physiological and pathological contexts.